In this direction of incorporating genetic findings into DME clinical practice, SDF-1-3′ (c801G > A) polymorphism may be an ideal biomarker and also a future therapeutic target for high-risk diabetic retinopathy patients, especially those carrying the SDF-1 (c801A) allele. Here, CXCL12 is linked to diabetic retinopathy.